Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + regorafenib + GM-CSF + sintilimab with or without IBI310 for first-line advanced pancreatic cancer
ChiCTR2100049459Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, regorafenib, sargramostim, sintilimab and IBI310 in pancreatic cancer (PC) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Objective response rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
gemcitabineregorafenibsargramostimsintilimabIBI310
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2100049459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049459.